Q-Med AB: Year-End Report 2009

January - December

  * Group revenues from sales of goods and royalties amounted to 1,364 (1,272)
    MSEK.
  * Earnings per share amounted to 6.89 (0.34) SEK.
  * Operating income amounted to 738 (50) MSEK.
  * In April 2009 Q-Med AB and Oceana Therapeutics, based in the US, entered
    into global agreements regarding commercialization rights to Deflux® and
    Solesta(TM). The agreements gave Q-Med an initial payment of 517 MSEK in
    total in June, partly as a purchase sum for Q-Med Scandinavia, Inc., the
    subsidiary that was divested within the framework of the agreements, and
    partly as payment for Oceana Therapeutics' share of certain study costs.
    Further revenues from the product development collaboration with Oceana
    Therapeutics were subsequently received during the fourth quarter and in
    total a net revenue of 505 MSEK has been recorded for the whole year in the
    Group income statement in the Other operating revenues row.
  * Revenues within the Esthetics product area amounted to 1,152 (1,037) MSEK
    and operating income was 252 (172) MSEK. For the Hospital Healthcare product
    area revenues from sales of goods and royalties were 212 (235) MSEK and
    operating income was 554 (-19) MSEK. Operating income includes the net
    revenue from the Oceana deal.
  * Net income after tax amounted to 685 (33) MSEK.


October - December

  * Group revenues from sales of goods and royalties amounted to 348 (336) MSEK
    during the fourth quarter and operating income amounted to 62 (-50) MSEK.
    Operating income for the Esthetics product area amounted to 57 (-5) MSEK and
    for the Hospital Healthcare product area operating income amounted to 17 (3)
    MSEK.
  * Net income after tax amounted to 51 (-44) MSEK during the fourth quarter.
  * On December 7 Q-Med AB and Oceana Therapetutics announced that the
    Solesta(TM) study for the treatment of patients with fecal incontinence,
    which will be used for registration of the product in the USA, had achieved
    both of its main objectives. Q-Med and Oceana Therapeutics intend to submit
    a premarket approval (PMA) application based on the results of the study to
    the FDA (US Food and Drug Administration) during the first quarter of 2010.


Events after the end of the period

  * Medicis, Q-Med's partner in North America, announced on February 3 that
    Restylane® with lidocaine (Restylane®-L) and Restylane Perlane(TM) with
    lidocaine (Perlane®-L) had been approved in the USA.
  * Q-Med has given notice to approximately 30 co-workers at the Uppsala
    facility as part of the company's work on changing the competence in the
    business and making it more effective.
  * The Board intends to propose to the Annual General Meeting a dividend of
    1.50 SEK per share.



Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: +46 70 974 9025

Alexander Kotsinas, Vice President and CFO
Tel: +46 73 500 1111

Future financial reports and calendar:

 Interim report January - March 2010     April 23, 2010

 Annual General Meeting                  April 28, 2010

 Interim report January - June 2010      July 22, 2010

 Interim report January - September 2010 October 22, 2010




Election committee:
Robert Wikholm,robert.wikholm@vinge.se <mailto:robert.wikholm@vinge.se>,
Chairman
Lars Bergkvist, Lannebo Fonder
Anders Milton
Kerstin Stenberg, Robur Fonder
Bengt Ågerup


February 12, 2010
Uppsala
Q-Med AB (publ.)


Bengt Ågerup
President and CEO


The information in this report is such as that which Q-Med is required to
disclose in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. The information was submitted for disclosure
at 7.30 a.m. on February 12, 2010.


Q-Med  AB  is  a  medical  device  company.  The company develops, manufactures,
markets,  and sells primarily medical implants. The majority of the products are
based  on the  company's patented  technology, NASHA(TM),  for the production of
stabilized  non-animal hyaluronic  acid. The  product portfolio  today contains:
Restylane®  for filling lines  and folds, contouring  and creating volume in the
face,  Macrolane(TM)  for  body  contouring,  Durolane(TM)  for the treatment of
osteoarthritis  of  the  hip  and  knee  joints,  Deflux®  for  the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and  Solesta(TM) for the treatment of fecal incontinence. Sales are made through
the company's own subsidiaries or distributors in over 70 countries. Q‑Med today
has about 650 coworkers, with approximately 400 at the company's head office and
production  facility  in  Uppsala,  Sweden.  Q-Med  AB  is listed in the Mid Cap
segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com
<mailto:info@q-med.com>. Web: www.q-med.com <http://www.q-med.com/>.


The full report with tables can be downloaded from the following link.



[HUG#1383837]